Encequidar mesylate hydrochloride
Based on 5 publication(s) in Google Scholar
Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models.
For research use only. We do not sell to patients.
- CAS No.: 2097125-58-9
- Formula: C39H42N6O11S
- Molecular Weight:802.85
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10550
Tariquidar
-
HY-15255
Zosuquidar
-
HY-50671
Zosuquidar trihydrochloride
-
HY-13646
Encequidar
-
HY-13646A
Encequidar mesylate
-
HY-10550A
Tariquidar methanesulfonate, hydrate
-
HY-17013
Dofequidar
-
HY-17013A
Dofequidar fumarate
-
HY-132189
Laniquidar
-
HY-50879
Elacridar
-
HY-10550R
Tariquidar (Standard)
-
HY-50880
Elacridar hydrochloride
Publications Citing Use of MedChemExpress (MCE) Encequidar mesylate hydrochloride
More
Biological Activity
Chemical Information
-
CAS No. 2097125-58-9
-
Molecular Weight 802.85
-
Formula C39H42N6O11S
-
SMILES
O=C1C=C(C(NC2=CC(OC)=C(C=C2C3=NN(C4=CC=C(CCN5CC6=CC(OC)=C(C=C6CC5)OC)C=C4)N=N3)OC)=O)OC7=C1C=CC=C7.O=S(O)(C)=O.O
-
Synonyms
HM30181 mesylate hydrochloride; HM30181A mesylate hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance. [Abstract]2021 Jan 12;12(1):312. PMID: 33436622 -
EMBO J
2024 Oct;43(19):4406-4436. PMID: 39160273 -
Crit Rev Anal Chem
A Critical Review on Advancement in Analytical Strategies for the Quantification of Clinically Relevant Biological Transporters. [Abstract]2022;52(7):1557-1571. PMID: 33691566 -
Hepatol Commun
Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC. [Abstract]2024 May 2;8(5):e0437. PMID: 38696353 -
Drug Metab Dispos
Encequidar is a multispecies gut-restricted P-glycoprotein inhibitor that delineates between intestinal secretion and biliary elimination in animals and predicts human disposition pathways. [Abstract]2026 Jan 16;54(3):100237. PMID: 41655312
Purity & Documentation
References
[1]. Bauer F, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol. 2012 Dec 5;696(1-3):18-27. [Content Brief]
[2]. Kim TE, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014 Sep;78(3):556-64. [Content Brief]
[3]. McCaw ZR, et al. Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. J Clin Oncol. 2023 Feb 20;41(6):1323. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Encequidar mesylate hydrochloride Related Classifications
HY-13646C Related Classifications
Powered by Bioz